Danish biotech Adcendo has accelerated its progression to a clinical-stage biotech by licensing an antibody-drug conjugate (ADC) from China's Multitude Therapeutics with potential in various forms of ...

Former Vice President Atiku Abubakar has emerged as the presidential candidate of the African Democratic Congress for the 2027 general election. The result was announced on Wednesday night at the ...

With traditional ADCs now fulfilling their potential to reshape the standard of oncology care, the bioconjugate community is doubling down on differentiation to ensure the next wave of ADCs delivers ...

You may have noticed an officer standing just behind the President of India at official events, state visits, or ceremonial functions. That officer holds a very important role as an Aide-de-Camp (ADC) ...

As speculations intensify over who emerges as the presidential candidate of the African Democratic Congress ahead of the 2027 general elections, the party’s leadership has insisted its immediate ...

ABUJA – In a bold move to reposition itself as a credible opposition platform, the African Democratic Congress (ADC) has approved the appointment of several prominent political figures, including ...

Antibody-drug conjugates (ADCs) are a growing class of biotherapeutics that have transformed targeted therapy, especially in oncology. By making use of monoclonal antibodies’ specificity to deliver ...

As a creative individual, Jordan Tassiello has a track record of achievements in founding her own business and working with large companies on writing, editing, design, content creation and campaigns.

NEW YORK--(BUSINESS WIRE)--Flowcode, the enterprise QR code platform delivering unique custom experiences, announced a partnership today with fast growing, emerging snack brand LOVE CORN, marking the ...

NEW YORK--(BUSINESS WIRE)--Flowcode, a marketing technology platform, has partnered with embedded insurance technology company REIN to streamline insurance purchases by making it easier to secure a ...

An open-label, multicenter, phase I study of ATG-022 in patients with advanced/metastatic solid tumors (CLINCH). The design, preclinical study and phase I dose escalation plan of a HER2 targeted ...